Duration of the anti-androgen in men undergoing six months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death

IMPORTANCE: Whether adding an anti-androgen (AA) to a luteinizing hormone-releasing hormone agonist in the radiotherapeutic management of unfavorable-risk prostate cancer (PC) reduces the risk of all cause and PC-specific mortality (ACM and PCSM) among men within differing comorbidity subgroups is u...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Prostate Cancer Prostatic Dis
Autores principales: Sanford, Nina N., Chen, Ming-Hui, Loffredo, Marian, Renshaw, Andrew, Kantoff, Philip W., D’Amico, Anthony V.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6171772/
https://ncbi.nlm.nih.gov/pubmed/27824043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/pcan.2016.53
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares